Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a report released on Sunday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Lipocine Stock Performance

Shares of NASDAQ LPCN opened at $3.18 on Friday. The company has a market cap of $17.01 million, a PE ratio of -4.18 and a beta of 1.42. Lipocine has a 52-week low of $2.91 and a 52-week high of $11.79. The firm’s 50 day moving average price is $3.66 and its 200-day moving average price is $4.51.

Institutional Investors Weigh In On Lipocine

An institutional investor recently raised its position in Lipocine stock. Geode Capital Management LLC grew its position in shares of Lipocine Inc. (NASDAQ:LPCN) by 6.0% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 57,464 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,248 shares during the quarter. Geode Capital Management LLC owned about 1.07% of Lipocine worth $280,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.